Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
22.64
+0.57 (2.56%)
Dec 20, 2024, 4:00 PM EST - Market closed
Neurogene Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Cost of Revenue | 57.65 | 44.39 | 47.51 | 42.26 |
| Gross Profit | -56.73 | -44.39 | -47.51 | -42.26 |
| Selling, General & Admin | 19 | 11.19 | 9.01 | 8.27 |
| Operating Expenses | 19 | 11.19 | 9.01 | 8.27 |
| Operating Income | -75.73 | -55.58 | -56.52 | -50.53 |
| Interest Expense | -0.01 | -0.01 | -0 | - |
| Interest & Investment Income | 6.98 | 2.95 | 1.34 | 0.02 |
| Other Non Operating Income (Expenses) | -0.74 | -0.03 | -0.01 | - |
| EBT Excluding Unusual Items | -69.5 | -52.67 | -55.19 | -50.52 |
| Other Unusual Items | 16.36 | 16.36 | - | - |
| Pretax Income | -53.25 | -36.32 | -55.19 | -50.52 |
| Net Income | -53.25 | -36.32 | -55.19 | -50.52 |
| Preferred Dividends & Other Adjustments | -49.97 | -49.97 | - | - |
| Net Income to Common | -3.28 | 13.65 | -55.19 | -50.52 |
| Shares Outstanding (Basic) | 13 | 0 | 0 | 4 |
| Shares Outstanding (Diluted) | 13 | 5 | 0 | 4 |
| Shares Change (YoY) | 116.71% | 1080.37% | -90.26% | - |
| EPS (Basic) | -0.25 | 27.76 | -139.88 | -12.47 |
| EPS (Diluted) | -0.26 | 2.93 | -139.88 | -12.47 |
| Free Cash Flow | -70.9 | -51.74 | -55.05 | -64.77 |
| Free Cash Flow Per Share | -5.51 | -11.11 | -139.54 | -15.99 |
| EBITDA | -72.45 | -52.29 | -53.32 | -49.59 |
| D&A For EBITDA | 3.28 | 3.3 | 3.2 | 0.95 |
| EBIT | -75.73 | -55.58 | -56.52 | -50.53 |
Source: S&P Capital IQ. Standard template.
Financial Sources.